Back to search results

Feasibility of Liquid Biopsy for Lung Cancer Screening

This study is looking at how practical and effective a "liquid biopsy" is for screening people at high risk for lung cancer. Currently, a low-dose CT (computed tomography) scan is used, but many eligible people don't get screened. A liquid biopsy is a blood test that can find tiny bits of DNA shed by cancer cells, potentially detecting lung cancer earlier. This trial wants to see if a positive liquid biopsy result might encourage more people to get a follow-up low-dose CT scan, which could lead to earlier diagnosis. You might be able to join if you are 50-80 years old, have a significant smoking history, and qualify for lung cancer screening with a low-dose CT scan. The main goal is to see how well liquid biopsy works for screening in a community setting.

Study design
This is an interventional study planning to enroll 108 participants. Participants will choose between two groups: one that starts with a liquid biopsy and another that starts with a low-dose CT scan.
What's involved
You would undergo either a liquid biopsy (blood test) or a low-dose CT scan of the chest. You might also complete surveys. If you have a positive liquid biopsy, you may be asked to get a low-dose CT scan.
Compensation
Not stated in the trial record.
Follow-up
After completing the study procedures, participants are followed up at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05384769

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

Recruiting
NAAges 50–80InterventionalScreening
City of Hope Medical Center
~108 participants
Updated 2025-10-07 on ClinicalTrials.gov
What's tested:Liquid BiopsyLow Dose Computed Tomography of the ChestSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Screening preference
Measured over Upon completion of home liquid biopsy or LDCT, an average of 4 weeks.

Conditions

Lung Carcinoma

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Dan Raz, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Dan Raz, MD
[email protected]
626-359-8111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented written informed consent of the participant.
Age 50-80 years.
Smoking history of \>= 20 pack-years and if quit, quit within 15 years.
Received referral for counseling for lung cancer screening and would qualify for LDCT.
Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center).
Willingness to provide blood sample.
English speaking.
Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT.

Exclusion

Symptoms of lung cancer.
Chest CT scan or chest positron emission tomography (PET)/CT within 12 months.
Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer.
Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.

What this trial measures

  • Screening preferenceUpon completion of home liquid biopsy or LDCT, an average of 4 weeks.

    The proportion of participants who agree to undergo lung cancer screening using liquid biopsy versus LDCT, with a feasibility threshold of at least 30% preferring liquid biopsy.